Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 9026 results

  1. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 18 May 2026.

    Technology appraisal guidance
    In consultation

  5. Pegunigalsidase alfa every 4 weeks for treating Fabry disease [TSID12346]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Siponimod for treating multiple sclerosis in people 10 to 17 years [TSID12317]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Elamipretide for treating Barth syndrome in people of any age [ID6545]

    In development Reference number: GID-TA11719 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  10. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development Reference number: GID-TA11019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]

    Awaiting development Reference number: GID-TA11945 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Luspatercept for treating haemoglobin H disease [ID6714]

    Awaiting development Reference number: GID-TA11940 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [ID6694]

    Awaiting development Reference number: GID-TA11933 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation